Technical Analysis for NTLA - Intellia Therapeutics, Inc.

Grade Last Price % Change Price Change
D 27.37 -3.29% -0.93
NTLA closed down 3.29 percent on Monday, March 18, 2024, on approximately normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
7 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
Stochastic Reached Oversold Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Bullish Engulfing Bullish -3.29%
Crossed Above 50 DMA Bullish -3.29%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -3.29%
NR7 Range Contraction -3.29%
Narrow Range Bar Range Contraction -3.29%
Inside Day Range Contraction -3.29%
Fell Below 50 DMA Bearish -0.55%

   Recent Intraday Alerts

Alert Time
Fell Below Previous Day's Low about 16 hours ago
Fell Below 50 DMA about 16 hours ago
50 DMA Support about 17 hours ago
Down 3% about 17 hours ago
Down 2 % about 17 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Intellia Therapeutics, Inc. Description

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Immune System Emerging Technologies Molecular Biology Genetics Hepatitis B Precision Medicine Metabolism Liver Disease Chimeric Antigen Receptor T Cell Amyloid Amyloidosis Chimeric Antigen Receptor Hematopoietic Stem Cell Hepatitis B Virus CRISPR Antitrypsin Deficiency Genome Editing Cell Product Inborn Errors Of Metabolism Cas9 Transthyretin Transthyretin Amyloidosis

Is NTLA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 47.475
52 Week Low 22.665
Average Volume 1,665,220
200-Day Moving Average 33.13
50-Day Moving Average 27.74
20-Day Moving Average 29.27
10-Day Moving Average 28.94
Average True Range 1.81
RSI (14) 44.44
ADX 16.75
+DI 20.15
-DI 20.61
Chandelier Exit (Long, 3 ATRs) 29.44
Chandelier Exit (Short, 3 ATRs) 30.76
Upper Bollinger Bands 33.39
Lower Bollinger Band 25.15
Percent B (%b) 0.27
BandWidth 28.15
MACD Line 0.05
MACD Signal Line 0.46
MACD Histogram -0.4138
Fundamentals Value
Market Cap 2.45 Billion
Num Shares 89.6 Million
EPS -5.34
Price-to-Earnings (P/E) Ratio -5.13
Price-to-Sales 50.43
Price-to-Book 2.44
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 28.87
Resistance 3 (R3) 28.93 28.49 28.62
Resistance 2 (R2) 28.49 28.11 28.46 28.54
Resistance 1 (R1) 27.93 27.87 27.71 27.87 28.45
Pivot Point 27.49 27.49 27.38 27.46 27.49
Support 1 (S1) 26.93 27.11 26.71 26.87 26.29
Support 2 (S2) 26.49 26.87 26.46 26.20
Support 3 (S3) 25.93 26.49 26.12
Support 4 (S4) 25.87